$TWST

WERNER ROBERT F. sold $280K of TWST

WERNER ROBERT F. (Chief Accounting Officer) sold 1,482 shares of Twist Bioscience Corp (TWST) at $188.88 ($0.28M total) on 2026-10-02.

Original reporting
SEC EDGAR · WERNER ROBERT F.
Published Oct 5, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosed sale is the primary new fact; no other companies are mentioned.

02

Market read

A modest insider sale by a senior officer may cause slight short‑term pressure on TWST but is unlikely to move the broader market.

03

What to watch

No 10b5‑1 plan was in place, suggesting the sale was discretionary.

Relevance 4/10Novelty 4/10Timing: after-hours filing

Background

Form 4 filings provide the first public disclosure of insider transactions, which traders monitor for signals.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Chief Accounting Officer sold 1,482 shares for $279,926, reducing his stake to 42,917 shares.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

C-level insider sales are watched by traders; the amount is modest but could influence short-term sentiment.

Market effects

Minimal impact on the biotech/genomics sector; the sale is company‑specific.

None

Low

Counterpoint

The sale could be routine portfolio rebalancing and not indicative of any negative outlook.

Key entities

  • Werner Robert F.

    Chief Accounting Officer of Twist Bioscience Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.